Key result
Post-revascularization LVEF improvement linked to ~5% lower mortality per 5% increase.
Why the study?
Coronary revascularization is recommended for ischemic cardiomyopathy, but the relations of revascularization-associated EF change to subsequent outcomes have not been elucidated.
Does improvement in left ventricular ejection fraction following coronary revascularization (PCI or CABG) reduce subsequent all-cause mortality and heart failure hospitalization days in patients with HFrEF?
Cohort (n=10,071)
Yes
Does improvement in left ventricular ejection fraction following coronary revascularization (PCI or CABG) reduce subsequent all-cause mortality and heart failure hospitalization days in patients with HFrEF?
In patients with HFrEF undergoing coronary revascularization, the degree of post-procedural LVEF improvement is associated with graded reductions in long-term mortality and heart failure hospitalization burden, particularly after PCI.
Answers are grounded in this paper and cite their sources.
May aid post-revascularization prognostication in HFrEF; hypothesis-generating for trials targeting LVEF recovery.
BACKGROUND: Coronary revascularization is recommended to treat ischemic cardiomyopathy. However, the relations of revascularization-associated ejection fraction (EF) change to subsequent outcomes have not been elucidated. METHODS: In 10 071 veterans (mean age 67 years; 1% women; 15% non-White) who underwent a first percutaneous coronary intervention (PCI) or coronary artery bypass grafting between January 1, 1995, and December 31, 2010, and had prerevascularization and postrevascularization EF measured, we calculated delta-EF (postprocedure EF-preprocedure EF). We related delta-EF as a continuous measure and as categories (≤-5, -5<delta-EF<0, delta-EF=0, 0<delta-EF<5, and delta-EF≥5) to death (using Cox regression) and heart failure hospitalization days (using negative binomial regression) in multivariable-adjusted models, for total sample, and PCI and coronary artery bypass grafting strata. RESULTS: Over follow-up (mean/maximum 5/14 years) 56% died. Each 5% improvement in delta-EF was associated with statistically significant reductions in death and heart failure hospitalization days of 5% (95% CI, 3%-7%) and 10% (95% CI, 5%-15%), respectively, in the total sample and 6% (95% CI, 4%-8%) and 10% (95% CI, 5%-16%), respectively, in the PCI subgroup. Patients in the highest delta-EF category had 27% (95% CI, 19%-34%) lower mortality (30% [95% CI, 21%-37%] lower in PCI stratum) and ≈40% lower heart failure hospitalization days in total sample and PCI stratum, compared with those in the lowest category. Relations of delta-EF and outcomes in coronary artery bypass grafting subgroup did not reach statistical significance. CONCLUSIONS: Revascularization-associated EF improvement was associated with significant reductions in mortality and heart failure hospitalization burden, particularly in the PCI subgroup.
No takes yet. Share an insight, caveat, or question.
A 2022 study conducted a cohort in Ischemic cardiomyopathy (CAD and HFrEF with LVEF <50%) (n=10,071). Revascularization-associated LVEF improvement (delta-EF per 5% increase or delta-EF categories) vs. Lowest delta-EF category (delta-EF ≤-5%) or continuous per 5% change was evaluated on All-cause mortality (HR 0.95 (5% reduction per 5% EF improvement), 95% CI 0.93-0.97, p=<0.05). Each 5% improvement in post-revascularization LVEF was associated with a 5% reduction in mortality and 10% reduction in heart failure hospitalization days.
Synapse has enriched 10 related papers. Consider them for comparative context: